Caribou Biosciences (CRBU) EBITDA Margin (2020 - 2025)
Historic EBITDA Margin for Caribou Biosciences (CRBU) over the last 6 years, with Q3 2025 value amounting to 1250.91%.
- Caribou Biosciences' EBITDA Margin rose 4079800.0% to 1250.91% in Q3 2025 from the same period last year, while for Sep 2025 it was 1697.93%, marking a year-over-year decrease of 4225500.0%. This contributed to the annual value of 1489.69% for FY2024, which is 11981300.0% down from last year.
- Per Caribou Biosciences' latest filing, its EBITDA Margin stood at 1250.91% for Q3 2025, which was up 4079800.0% from 2033.18% recorded in Q2 2025.
- Caribou Biosciences' 5-year EBITDA Margin high stood at 41.62% for Q3 2023, and its period low was 2033.18% during Q2 2025.
- Its 5-year average for EBITDA Margin is 1038.51%, with a median of 829.7% in 2021.
- In the last 5 years, Caribou Biosciences' EBITDA Margin skyrocketed by 8184400bps in 2021 and then plummeted by -16172800bps in 2024.
- Quarter analysis of 5 years shows Caribou Biosciences' EBITDA Margin stood at 727.39% in 2021, then rose by 1bps to 717.01% in 2022, then tumbled by -31bps to 941.37% in 2023, then crashed by -84bps to 1734.42% in 2024, then grew by 28bps to 1250.91% in 2025.
- Its last three reported values are 1250.91% in Q3 2025, 2033.18% for Q2 2025, and 1703.31% during Q1 2025.